All News
#acr19 @rheumnow Hench lecture: Dr Reveille
HLAB15 may be a marker for peripheral arthritis in pts w/AS (OR 1.9)
k dao KDAO2011 ( View Tweet)
Bullish on value of Polygenic Risk scores to help diagnose Axial SpA (not commercially available yet)
#ACR19 @rheumnow 5T004 Reveille https://t.co/OfQYzx6yGL
Dr Irwin Lim _connectedcare ( View Tweet)
VERVE results - Live zoster vaccine safe and effective in >600 patients with autoimmune diseases treated wth TNFi abstr#0824 @RheumNow #ACR19
Cassandra Calabrese CCalabreseDO ( View Tweet)
Buyon reminds us how highly sensitive ELISA based anti-DNA assays are, caution required because more sensitive tests are often negative (crithidia/RIA) #ACR19 @RheumNow Abs 5T002 https://t.co/XN8Sfy1yHJ
Philip Robinson philipcrobinson ( View Tweet)
2.9% of this cohort had ONSET of Inflammatory Back pain after age of 50. We don’t study this group.
#ACR19 @rheumnow 5T004 Reveille https://t.co/p023BlGxPN
Dr Irwin Lim _connectedcare ( View Tweet)
@SurajDhoot2 @RheumNow the speaker stated most think a tophus is just a crystal collection, but within the tophus there are a lot of biologic activity: cytokines, fibroblasts, macrophages.... driven by the crystals. The treatment is the same (ULT)but it might also explain why IL-1 inh helps inflmm
k dao KDAO2011 ( View Tweet)
#acr19 @rheumnow Hench Lecture w/Dr J Reveille on back pain to HLA B27
20% of people 20-50 yrs old in US have chronic back pain. How many of you have back pain now?
k dao KDAO2011 ( View Tweet)
Important point that we must adjust for duration of treatment when looking at irAEs as a biomatker for tumor response to ICI- even when you do, however, any grade irAE is associated with better outcome! #ACR19 @LCalabreseDO @CCalabreseDO @drdavidliew
Laura Cappelli cappelliMD ( View Tweet)
@cappelliMD @LCalabreseDO @CCalabreseDO Jeffrey Weber today at #ACR19: "I'm a T cell chauvinist... turns out that B cells are extraordinarily important in the onset of irAEs." Autoantibodies important in irAEs - Jeffrey Weber's convinced!
shout out to @jessbq @ONJ_TILs
David Liew drdavidliew ( View Tweet)
PMR treatment with no oral steroids, low dose MTX and occasional steroid injections? Surprising and intriguing: little success previously in non-steroid paradigm in PMR, more data on this please, def worth further testing!
Hospital 12 de Octubre, Madrid #ACR19 ABST0742 @RheumNow https://t.co/I15GA4gjPw
David Liew drdavidliew ( View Tweet)
Takayasu's arteritis isn't just one, homogenous disease - and different phenotypes have different outcomes. Interesting from @petercgrayson's group at @NIH_NIAMS #ACR19 ABST0753 @RheumNow https://t.co/sWxUGaCRq2
David Liew drdavidliew ( View Tweet)
You heard it from the oncologist- autoimmune disease is NOT an exclusion criterion for being treated with immune checkpoint inhibitors! Flare is common but manageable #ACR19
Laura Cappelli cappelliMD ( View Tweet)
Here are the results of the poll. Thanks for participating. We look forward to more studies that will help us answer this important question 🤫 #ACR19 @RheumNow https://t.co/q3AJZS6spj
Dr. Antoni Chan synovialjoints ( View Tweet)
GiACTA
What happened when weekly TCZ stopped?
42% maintained clinical remission on NO treatment at end 2yr Part2
What happened when Pred stopped (this happened in part1)?
Taper 26wk: 32% no flare over yr
Taper 52wk: 51% no flare over that yr
#ACR19 @rheumnow Abst0808
Dr Irwin Lim _connectedcare ( View Tweet)
GiACTA 1: blinded injections stopped wk52
Part 2: 2yrs
Time to flare after remission
Most flares in part 1 in those randomised to GC alone
Lowest cumulative GC doses over 3y in TCZ-QW (50% less)
#ACR19 @rheumnow Abst0808
Dr Irwin Lim _connectedcare ( View Tweet)
GiACTA Part 1 at conclusion, different gps obvious:
In remission no treatment
In remission on treatment
Recently active, on treatment
GiACTA Part 2 Aims:
Long term safety of TCZ-treated GCA
Explore maintenance of efficacy after TCZ discontinuation
#ACR19 @rheumnow Abst0808
Dr Irwin Lim _connectedcare ( View Tweet)
FINCH3: in this cohort naive to MTX pre-trial, interesting that safety looks good! Maybe too early to tell
#ACR19 @rheumnow Abst0927 #ACRbest https://t.co/QCdC8UQR3f
Dr Irwin Lim _connectedcare ( View Tweet)
Fenebrutinib- Conclusions from phase2. How does this compare to our other small molecules? Will trial development continue?
#ACR19 @rheumnow Abst0929 https://t.co/5ahkmSB11X
Dr Irwin Lim _connectedcare ( View Tweet)
Awesome to hang out with my friends @psufka and @DrBhana to record an episode of ACR on Air on location at #ACR19 ! https://t.co/WeolRLGs17
Jonathan Hausmann MD hausmannMD ( View Tweet)
25% of SLE and RA patients at this academic practice were receiving HCQ above recommended doses, by @SkorupaTara & @RobShmerling #ACR19 @rheumnow #Abstr #ACRBest https://t.co/pq379l9ZPH
Jonathan Hausmann MD hausmannMD ( View Tweet)